Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures


BioMarck has successfully raised equity capital from private sources.

Biomarck has been awarded a succession of grants under the auspices of the National Institute of Health (NIH). These include a Phase I SBIR grant for $100,000 in 2003, a Phase II SBIR grant for $1,228,000 in 2004, a Phase III SBIR grant for $2,990,000 in 2006, a SBIR grant for $3,000,000 in 2014 and a STTR grant for $201,503 in 2014. The SBIR grant process involves review of data and proposed development plans by a group of experts in the respiratory field. Excellent priority scores from this review group and positive funding decisions support the fact that the respiratory community (scientific and clinical) is eager to support the development of BIO-11006 Inhalation Solution.


Except for the historical information set forth herein, the matters set forth on this Website, including statements regarding the Company’s plans and expectations for BIO-11006 and the other peptides in its portfolio, contain predictions, estimates and other forward looking statements. These forward looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risk related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks.